Richard J. Hawkins

This profile gathers the share dealings of Richard J. Hawkins across 4 companies, led by Sciclone Pharmaceuticals Inc, Lumos Pharma, Inc. and Savara Inc. Over a trading history stretching from 30 April 2009 to 1 October 2026, the count stands at 68 filings.

On the open market, the record shows 9 purchases worth €149k and 14 sales worth €1.9M. Taken together, the sales exceed the purchases by €1.8M. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Outside the open market, there are 25 share grants and 17 option exercises.

Half of the purchases are above €7,684 and half below. Of 9 purchases, 8 formed part of a group of insiders buying within 30 days of each other. When several insiders buy within a few weeks of each other, analysts speak of a cluster purchase. Ninety days after publication, 3 purchases show a median change of -35.3%, with the price up in 33% of them. These figures describe past trades and do not predict future prices.

Most recently, on 1 October 2026, the filings show an option exercise in Cerenome, Inc. The most recent open-market purchase was published on 23 June 2025, 488 days ago. Typically, a trade is published a median of 2 days after it takes place. US insiders must file a Form 4 within two business days of a trade. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.